BMRN

In September 2026, BioMarin appointed Robert Plenge to its Board of Directors, announced positive Phase 3 VOXZOGO study results, and completed the acquisition of Alesta Therapeutics. In August 2026, the company reported second-quarter financial results with total revenues increasing 20% year-over-year to $990 million, leading to an increased full-year VOXZOGO revenue guidance of at least $1 billion, and the stock gained 3.8% following the earnings announcement. In May 2026, first-quarter financial results showed total revenues of $766 million, an increase of $21 million from the previous year, driven by government orders, increased patient demand for Enzyme Therapies, and new VOXZOGO patients, with the acquisition of Amicus Therapeutics noted for strengthening growth rates. In December 2025, BioMarin's stock experienced its largest daily move in the past year, increasing by 17.7%. Overall, the stock has seen a 17.5% increase over the past year from September 22, 2025, to September 22, 2026.